3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
2
Sarcoma
1
Head & Neck
1
Breast
1
Conditions
Breast Neoplasms
25
Breast Neoplasms, Male
6
Triple Negative Breast Neoplasms
4
Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Squamous Cell Carcinoma of Head and Neck
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Lung Neoplasms
2
Colonic Neoplasms
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thrombocytosis
1
Thoracic Neoplasms
1
Small Cell Lung Carcinoma
1
Salivary Gland Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Rectal Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Oligodendroglioma
1
Neuroectodermal Tumors, Primitive
1
Neoplasms by Site
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Mesothelioma, Malignant
1
Interventions
pembrolizumab
14
Gemcitabine
8
Docetaxel
7
Nivolumab
6
durvalumab
5
Cyclophosphamide
5
130-nm albumin-bound paclitaxel
5
atezolizumab
4
Magnetic Resonance Spectroscopy
4
Irinotecan
4
sargramostim
3
aldesleukin
3
Specimen Handling
3
Radiotherapy
3
Paclitaxel
3
Ipilimumab
3
Fulvestrant
3
Cisplatin
3
Carboplatin
3
venetoclax
2
temsirolimus
2
talazoparib
2
spartalizumab
2
olaparib
2
liposomal doxorubicin
2
fludarabine phosphate
2
cabozantinib
2
budigalimab
2
avelumab
2
Vinorelbine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Small Cell Lung Carcinoma
×
Erlotinib Hydrochloride
×
Breast
×
Clear all
NCT05827614
2026-01-23
POTENTIATE
Boundless Bio, Inc.
Phase 1
Active not recruiting
85 enrolled